ClinicalTrials.gg

Program

experimental vaccine

Also written as “Low-dose experimental vaccine”, “High-dose experimental vaccine” and “Experimental vaccine”.

Its studies are mostly in Meningitis, Meningococcal · Herpes Zoster · Poliomyelitis · Hand, Foot and Mouth Disease, led by Sinovac Biotech.

Furthest: phase 4, since May 25, 20227 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech75 open or runningphase 4since May 25, 2022May 18, 2022Nov 2026phase 3 · NCT07505888

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2022First study: phase 3 study in PoliomyelitisFirst studyNCT05386810 · 1,572 enrolled · China
  2. May 25, 2022Phase 4 study in Hand, Foot and Mouth DiseaseNCT05397587 · 474 enrolled · China
  3. Jan 26, 2026Phase 2 study in Herpes ZosterNCT07400003 · 519 planned · China
  4. Mar 13, 20264 phase 3 studies in Meningitis, MeningococcalNCT07505888, NCT07505836, NCT07505823 and 1 more

Ahead

  1. Nov 2026Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505888
  2. Jan 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505836
  3. Apr 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505823
  4. Apr 2027Primary completion: phase 3 study in Meningitis, MeningococcalNCT07505810

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“experimental vaccine”name, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07505888Meningitis, Meningococcal · China3Active, not recruitingNov 2026660
NCT07505836Meningitis, Meningococcal · China3RecruitingJan 20271,040
NCT07505823Meningitis, Meningococcal · China3RecruitingApr 20271,040
NCT07505810Meningitis, Meningococcal · China3RecruitingApr 2027880
NCT07400003Herpes Zoster · China2RecruitingMay 31, 2026519
NCT05397587Hand, Foot and Mouth Disease · China4UNKNOWNJul 30, 2025474
NCT05386810Poliomyelitis · China3CompletedOct 8, 20221,572

How it is read

Names in the registry

  • “experimental vaccine”, 4 entries
  • “Low-dose experimental vaccine”, 1 entry
  • “High-dose experimental vaccine”, 1 entry
  • “Experimental vaccine”, 1 entry
  • “Experimental Vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.